Acquired Immunodeficiency Syndrome (AIDS) Global Market Report 2025

The acquired immunodeficiency syndrome (AIDS) market size has grown strongly in recent years. It will grow from $32.09 billion in 2024 to $33.85 billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth during the historic period can be attributed to the rising rates of HIV infections, increased government funding for HIV treatment, the expansion of global awareness programs, improvements in diagnostic capabilities, and growing support from non-governmental organizations.

The acquired immunodeficiency syndrome (AIDS) market size is expected to see strong growth in the next few years. It will grow to $41.57 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The projected growth in the forecast period can be attributed to the rising demand for long-acting injectable therapies, increasing adoption of pre-exposure prophylaxis (PrEP), growing investment in HIV cure research, the expansion of telemedicine services for HIV care, a heightened focus on personalized medicine, and increased awareness about early HIV diagnosis. Key trends during this period include a shift toward single-tablet regimens, a growing preference for injectable and implantable HIV treatments, a rising demand for digital health solutions in HIV management, increased interest in functional HIV cure strategies, and the expanding role of artificial intelligence in drug discovery.

The increasing rates of HIV infections are expected to drive the growth of the acquired immunodeficiency syndrome (AIDS) market. HIV infections refer to the condition caused by the human immunodeficiency virus, which weakens the immune system, making it harder for the body to fight infections and diseases. The rising rates of HIV infections can be attributed to factors such as unprotected sexual intercourse with an infected individual, sharing needles, receiving contaminated blood products, having multiple sexual partners, and a weakened immune system or existing sexually transmitted infections. Management of AIDS helps patients with HIV by promoting early diagnosis, improving access to effective antiretroviral therapies, enhancing prevention strategies, and strengthening healthcare systems to better control the spread of the virus. For example, in November 2024, the European Centre for Disease Prevention and Control (ECDC) reported 112,883 new HIV diagnoses in 2023 across 47 out of 53 countries in the region, with 24,731 of these cases occurring in the European Union/European Economic Area (EU/EEA). This marks a 2.4% increase in the crude rate of HIV diagnoses compared to the previous year, indicating the growing prevalence of HIV infections and contributing to the expansion of the AIDS market.

Companies operating in the AIDS market are focusing on the development of innovative therapies such as long-acting injectables to improve patient adherence, reduce dosing frequency, and offer a more convenient alternative to daily oral antiretroviral treatments. These injectables are designed to release their active ingredients slowly over time, which allows for less frequent dosing compared to traditional oral medications. For example, in January 2025, GSK plc., a UK-based pharmaceutical company, received approval from the European Commission for a long-acting injectable treatment consisting of Vocabria (cabotegravir) and Rekambys (rilpivirine). This treatment, approved for adolescents aged 12 years and older living with HIV, is administered through an intramuscular injection, typically every one or two months, depending on the treatment plan. This long-acting formulation can improve adherence rates among adolescents who may struggle with daily pill regimens.

In November 2024, Gilead Sciences Inc., a U.S.-based biopharmaceutical company, acquired investigational assets for the HTI therapeutic HIV vaccine from AELIX Therapeutics. Through this acquisition, Gilead aims to enhance its HIV treatment portfolio by advancing research into functional HIV cures and potentially reducing the reliance on lifelong antiretroviral therapy. AELIX Therapeutics, based in Spain, focuses on developing treatments and vaccines for AIDS.

Major players in the acquired immunodeficiency syndrome (aids) market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi SA, Bristol-Myers Squibb Company, Abbott, GSK plc, Takeda Pharmaceuticals, Gilead Sciences, Viatris Inc., Teva Pharmaceuticals, Aurobindo Pharma, Cipla Ltd, Shionogi and Co., Dr. Reddy's Laboratories, Lupin, Hetero Drugs Limited, Glenmark Pharmaceuticals Limited, ViiV Healthcare.

North America was the largest region in the acquired immunodeficiency syndrome (AIDS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in acquired immunodeficiency syndrome (AIDS) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the acquired immunodeficiency syndrome (AIDS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Acquired immunodeficiency syndrome (AIDS) is a chronic, life-threatening condition caused by the human immunodeficiency virus (HIV), which progressively weakens the immune system by attacking and destroying CD4 T cells. This leaves the body susceptible to opportunistic infections, severe illnesses, and certain cancers unless effective antiretroviral treatment (ART) is administered. AIDS management involves a combination of ART, regular monitoring of immune function, prevention of opportunistic infections, and comprehensive healthcare support to enhance patient outcomes and quality of life.

The main types of acquired immunodeficiency syndrome (AIDS) include human immunodeficiency virus 1 (HIV-1) and human immunodeficiency virus 2 (HIV-2). HIV-1 is a retrovirus that primarily infects CD4+ T cells, leading to progressive immunodeficiency and, if untreated, the development of AIDS. Drugs used in treating AIDS include nucleoside-analog reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, fusion inhibitors, CCR5 antagonists, post-attachment inhibitors, protease inhibitors, integrase inhibitors, and pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP). These drugs are administered orally or parenterally and are used in various settings, including hospital pharmacies, retail pharmacies, and others, with distribution via both offline and online channels.

The acquired immunodeficiency syndrome (AIDS) market research report is one of a series of new reports that provides acquired immunodeficiency syndrome (AIDS) market statistics, including acquired immunodeficiency syndrome (AIDS) industry global market size, regional shares, competitors with a acquired immunodeficiency syndrome (AIDS) market share, detailed acquired immunodeficiency syndrome (AIDS) market segments, market trends and opportunities, and any further data you may need to thrive in the acquired immunodeficiency syndrome (AIDS) industry. This acquired immunodeficiency syndrome (AIDS) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acquired immunodeficiency syndrome (AIDS) market consists of sales of products such as long-acting injectable antiretrovirals, broadly neutralizing antibodies (bNAbs), therapeutic HIV vaccines, latency-reversing agents, capsid inhibitors, attachment inhibitors, maturation inhibitors, and pharmacokinetic enhancers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.